Related Experiment Video
Updated: Jul 15, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Market power and state costs of HIV/AIDS drugs
Arleen A Leibowitz1, Neeraj Sood
1UCLA School of Public Affairs, 3250 Public Policy Building, Los Angeles, CA 90095-1656, USA. arleen@ucla.edu
Abstract:
We examine whether U.S. states can use their market power to reduce the costs of supplying prescription drugs to uninsured and underinsured persons with HIV through a public program, the AIDS Drug Assistance Program (ADAP). Among states that purchase drugs from manufacturers and distribute them directly to clients, those that purchase a greater volume pay lower average costs per prescription. Among states depending on retail pharmacies to distribute drugs and then claiming rebates from manufacturers, those that contract with smaller numbers of pharmacy networks have lower average costs. Average costs per prescription do not differ between the two purchase methods.
Related Concept Videos
Dose-Response Relationship: Potency and Efficacy
Drug Control Governance: Regulatory Bodies and Their Impact
Retrovirus Life Cycles
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Products: Biologics, Biosimilars and Interchangeables
Therapeutic Drug Monitoring: Affecting Factors

